Drug Trial Radar · NCT07216378
Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 2 years, up to 11 years
Summary
As written by the sponsor on the registry.
The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Conditions
- Hereditary Angioedema
Interventions
SebetralstatDrug
Oral Plasma Kallikrein Inhibator
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
KalVista Investigative Site
San Diego, California · Available
KalVista Investigative Site
Evansville, Indiana · Available
KalVista Investigative Site
Wheaton, Maryland · Available
KalVista Investigative Site
St Louis, Missouri · Available
KalVista Investigative Site
Knoxville, Tennessee · Available
KalVista Investigative Site
San Antonio, Texas · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.